On Oct 10, Vaccinex ot Letter From Nasdaq Listing Staff Stating That Co Has Not Regained Compliance With Minimum Bid Price Standard
Portfolio Pulse from Benzinga Newsdesk
Vaccinex has received a letter from Nasdaq stating that the company has not regained compliance with the minimum bid price standard, according to an SEC filing.
October 13, 2023 | 9:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vaccinex's failure to regain compliance with Nasdaq's minimum bid price standard could potentially lead to its delisting.
Vaccinex's failure to meet Nasdaq's minimum bid price standard is a serious issue. If the company cannot regain compliance, it may face delisting from the Nasdaq exchange, which would significantly impact its stock's liquidity and potentially its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100